title: Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.
abstract: OBJECTIVE
  To assess the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to insulin in Asian patients with type 2 diabetes mellitus (T2DM).
  
  
  METHODS
  This was a post hoc analysis of a subgroup of Asian patients from a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in T2DM patients inadequately controlled by stable insulin therapy, with or without metformin. A total of 173 patients were randomized 1:1 to receive treatment with vildagliptin 50 mg bid (n = 87) or placebo (n = 86) for 24 wk. Changes in HbA1c and fasting plasma glucose (FPG), from baseline to study endpoint, were analyzed using an analysis of covariance model. Change from baseline to endpoint in body weight was summarized by treatment. Safety and tolerability of vildagliptin was also evaluated.
  
  
  RESULTS
  After 24 wk, the difference in adjusted mean change in HbA1c between vildagliptin and placebo was 0.82% (8.96 mmol/mol; P < 0.001) in Asian subgroup, 0.85% (9.29 mmol/mol; P < 0.001) in patients also receiving metformin, and 0.73% (7.98 mmol/mol; P < 0.001) in patients without metformin, all in favor of vildagliptin. There was no significant difference in the change in FPG between treatments. Weight was stable in both treatment groups (+0.3 kg and -0.2 kg, for vildagliptin and placebo, respectively). Overall, vildagliptin was safe and well tolerated with similarly low incidences of hypoglycemia (8.0% vs 8.1%) and no severe hypoglycemic events were experienced in either group.
  
  
  CONCLUSIONS
  In Asian patients inadequately controlled with insulin (with or without concomitant metformin), insulin-vildagliptin combination treatment significantly reduced HbA1c compared with placebo, without an increase in risk of hypoglycemia or weight gain.
authors: Plamen Kozlovski, Novartis Pharma AG, CH-4002 Basel, Switzerland.
authors: Plamen
authors: P
authors: Kozlovski
authors: James
authors: J
authors: Foley
authors: Qing
authors: Q
authors: Shao
authors: Valentina
authors: V
authors: Lukashevich
authors: Wolfgang
authors: W
authors: Kothny
keywords: Asian; DPP-4 inhibitor; Hypoglycemia; Insulin; Oral antidiabetic drug; Type 2 diabetes; Vildagliptin
references: Diabetes Res Clin Pract. 2007 Apr;76(1):132-8
references: 17223217
references: Diabetes Obes Metab. 2008 Nov;10(11):1047-56
references: 18284434
references: Diabetes Res Clin Pract. 2009 Feb;83(2):233-40
references: 19118913
references: Diabetes Obes Metab. 2013 Mar;15(3):252-7
references: 23039321
references: Chin Med J (Engl). 2008 Apr 20;121(8):677-81
references: 18701017
references: Curr Med Res Opin. 2012 Apr;28(4):513-23
references: 22313154
references: Vasc Health Risk Manag. 2013;9:57-64
references: 23431062
references: Diabetes Obes Metab. 2008 Nov;10(11):1114-24
references: 18355325
references: Diabetes Ther. 2011 May;2(2):51-66
references: 22127800
references: Diabetes Obes Metab. 2012 Aug;14(8):737-44
references: 22369287
references: Diabetes Obes Metab. 2011 Sep;13(9):775-83
references: 21507182
references: Diabetes Care. 2007 Feb;30(2):217-23
references: 17259484
references: Diabetes Obes Metab. 2007 May;9(3):428-34
references: 17391171
references: Diabetes Res Clin Pract. 2010 Sep;89(3):216-23
references: 20537746
references: Diabetes Obes Metab. 2010 Aug;12(8):683-8
references: 20590745
references: Diabet Med. 2002 Dec;19(12):978-85
references: 12647837
references: Diabetes Obes Metab. 2009 May;11 Suppl 2:9-17
references: 19385979
references: Diabetes Obes Metab. 2012 Sep;14(9):795-802
references: 22443183
references: JAMA. 2009 May 27;301(20):2129-40
references: 19470990
references: Diabetes Obes Metab. 2009 Dec;11(12):1145-52
references: 19758359
references: Diabetes Res Clin Pract. 2011 Dec;94(3):352-63
references: 22153567
references: Curr Med Res Opin. 2008 Feb;24(2):507-14
references: 18184454
references: J Clin Endocrinol Metab. 2009 Apr;94(4):1236-43
references: 19174497
references: Diabetes Obes Metab. 2010 Feb;12(2):167-77
references: 20092585
references: Vasc Health Risk Manag. 2010 Aug 09;6:541-8
references: 20730070